top of page
Market Entry Strategy

UroPharma’s initial strategy is to bring dtb therapeutics to people with MS in the US, UK and Europe


UroPharma’s own market research indicates that many people with Multiple Sclerosis MS (who are already self-catheterizing) will choose dtb therapy throughout their lives because of its effectiveness and minimal side effect profile, which translates to a potential recurring revenue stream for UroPharma.

bottom of page